MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a large decrease in short interest in June. As of June 30th, there was short interest totaling 124,038 shares, a decrease of 70.1% from the June 15th total of 414,844 shares. Approximately 2.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 204,942 shares, the days-to-cover ratio is presently 0.6 days.

MetaVia Price Performance

Shares of MTVA traded down $0.06 during midday trading on Tuesday, hitting $1.93. The stock had a trading volume of 473,840 shares, compared to its average volume of 1,966,418. The stock’s 50 day moving average is $1.92 and its 200 day moving average is $2.55. The firm has a market cap of $9.96 million, a PE ratio of -0.37 and a beta of 0.97. MetaVia has a 1 year low of $0.97 and a 1 year high of $19.03.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). As a group, equities research analysts expect that MetaVia will post -2.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on MTVA. HC Wainwright reiterated a “buy” rating on shares of MetaVia in a research report on Friday. Wall Street Zen upgraded MetaVia to a “sell” rating in a research report on Saturday, June 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.